All News
Top NIH Official Forced Out; Trump Sued by Fired HHS Watchdog; E. Coli Vaccine Flops
(MedPage Today) -- Note that some links may require registration or subscription. NIH's longtime second-in-command, Larry Tabak, DDS, PhD, was forced to retire from government service.
Read MoreThe biotech news stories you need to read today
The risk of pharma bribery, the risk of brain drain, and other risks (and rewards) in the biotech landscape this week.
Read MorePeople with alcohol-use disorder drank less on Ozempic, small study shows
And other health news stories to read this Thursday.
Read MoreSTAT+: Pharmalittle: We’re reading about fears of a Trump-inspired brain drain, Ozempic’s effect on drinking, and more
Scientists fear disruptive Trump policies could lead to a brain drain and undermine the nation's leadership in biomedicine
Read MoreWindfarm profits should be used to screen Scots for rare diseases, says scientist
Geneticist who discovered hotspots of illnesses in Scottish islands calls for redirection of community benefit fundsA leading geneticist has called for the profits from windfarms to be used for the ma
Read MoreSTAT+: Biotech is in a dark place
Biotech and drug stocks, collectively, are down an average of 16% over the past three months. The closely watched XBI index is down 19% in the same time period.
Read MoreRepublican States Claim Zero Abortions. A Red-State Doctor Calls That ‘Ludicrous.’
In several red states, officials say few or no abortions happened in 2023, raising alarm among researchers about the politicization of vital statistics.
Read MoreTop California Democrats Clash Over How To Rein In Drug Industry Middlemen
Frustrated by spiraling drug costs, California lawmakers want to increase oversight of pharmaceutical industry intermediaries known as pharmacy benefit managers.
Read MoreMontana Looks To Regulate Prior Authorization as Patients, Providers Decry Obstacles to Care
Patients and providers say health insurers’ preapproval requirements lead to delays and denials of needed medical treatments. Insurers argue that prior authorization keeps costs down.
Read More